Oncternal Therapeutics, Inc.
Hedge Funds Holdings
Last updated:
Oncternal Therapeutics, Inc.‘s stocks are currently a part of 56 hedge funds’ portfolios, which represents 16.34% of the total amount of its stocks outstanding. This makes up a total of 8.85M shares of Oncternal Therapeutics, Inc.. Compared to the previous quarter, the number fell by -5.75% or -540.18K shares fewer. As for the holding position changes, 19.64% (11) of current hedge fund investors increased the number of shares held, 23.21% (13) of current holders sold a part of the shares held, and 19.64% (11) closed the holdings completely. 13 hedge funds are new holders of Oncternal Therapeutics, Inc. stock in Q4 2022, it is 23.21% of total holders.
Hedge funds holding Oncternal Therapeutics (Q2 2019 – Q4 2022)
Q2 2019 | 23 |
---|---|
Q3 2019 | 21 |
Q4 2019 | 22 |
Q1 2020 | 21 |
Q2 2020 | 19 |
Q3 2020 | 21 |
Q4 2020 | 52 |
Q1 2021 | 64 |
Q2 2021 | 84 |
Q3 2021 | 75 |
Q4 2021 | 82 |
Q1 2022 | 75 |
Q2 2022 | 68 |
Q3 2022 | 55 |
Q4 2022 | 56 |
Hedge funds changes in Oncternal Therapeutics positions (Q2 2019 – Q4 2022)
Q2 2019 | 23 | 0 | 0 | 0 | 0 |
---|---|---|---|---|---|
Q3 2019 | 8 | 5 | 5 | 10 | -7 |
Q4 2019 | 3 | 4 | 9 | 2 | 4 |
Q1 2020 | 3 | 5 | 6 | 4 | 3 |
Q2 2020 | 1 | 6 | 4 | 3 | 5 |
Q3 2020 | 4 | 4 | 4 | 2 | 7 |
Q4 2020 | 36 | 8 | 2 | 5 | 1 |
Q1 2021 | 29 | 18 | 11 | 14 | -8 |
Q2 2021 | 27 | 24 | 18 | 8 | 7 |
Q3 2021 | 9 | 28 | 22 | 18 | -2 |
Q4 2021 | 18 | 22 | 25 | 11 | 6 |
Q1 2022 | 13 | 22 | 25 | 20 | -5 |
Q2 2022 | 19 | 17 | 19 | 25 | -12 |
Q3 2022 | 3 | 10 | 19 | 16 | 7 |
Q4 2022 | 13 | 11 | 13 | 11 | 8 |
Hedge funds changes in Oncternal Therapeutics stock options (Q2 2019 – Q4 2022)
Q2 2019 | 129,000 | 0 |
---|---|---|
Q3 2019 | 5,000 | 0 |
Q4 2019 | 0 | 0 |
Q1 2020 | 0 | 0 |
Q2 2020 | 0 | 0 |
Q3 2020 | 0 | 0 |
Q4 2020 | 320,000 | 256,000 |
Q1 2021 | 1,409,000 | 2,853,000 |
Q2 2021 | 1,335,000 | 2,083,000 |
Q3 2021 | 1,857,000 | 882,000 |
Q4 2021 | 223,000 | 118,000 |
Q1 2022 | 60,000 | 189,000 |
Q2 2022 | 38,000 | 115,000 |
Q3 2022 | 21,000 | 0 |
Q4 2022 | 27,800 | 1,300 |